Abstract

BackgroundThe fibrinogen-to-albumin ratio (FAR) has been identified as a new inflammatory marker for predicting the risk of cardiovascular diseases. Nevertheless, its prognostic relevance in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) remains uncertain. MethodsThis study included a total of 1031 hospitalized patients diagnosed with MINOCA, enrolled consecutively. The primary outcome was the occurrence of major adverse cardiovascular events (MACE). Based on the median FAR value, patients were divided into high FAR (FARH) and low FAR (FAR-L) groups. Baseline clinical characteristics and the incidence of adverse events during the follow-up period were compared between the two groups. Various statistical methods were applied, including restricted cubic spline modeling, Kaplan-Meier survival analysis, and Cox proportional hazards modeling. ResultsThe median follow-up duration was 42.3 months, during which 157 patients (15.2 %) experienced MACE. The FAR-H group had a significantly higher incidence of MACE compared to the FAR-L group (21.2 % vs. 9.3 %, p < 0.001). Multivariate Cox regression analysis revealed that a higher FAR was an independent predictor of long-term MACE in MINOCA patients (hazard ratio = 2.76, 95 % confidence interval: 1.95–3.89, p < 0.001), after adjusting for relevant clinical variables. ConclusionsAn elevated FAR is linked to a poor long-term prognosis in patients with MINOCA.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.